



I hereby certify that this correspondence is being deposited with the United States Patent and Trademark Office as first class mail in an envelope addressed to:

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On December 13, 2005

TOWNSEND and TOWNSEND and CREW LLP

By: Jo Ann Honcik Dallara
Jo Ann Honcik Dallara

PATENT
Attorney Docket No.: 019633-000117US
Client Ref. No.: NRC00072.1USD6
Customer No.: 20350

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GILBERT and WAKARCHUK

Application No.: 10/734,719

Filed: December 11, 2003

For: NUCLEIC ACIDS ENCODING
SIALYTRANSFERASES FROM C.
jejuni

Customer No. 20350

Confirmation No. 2376

Examiner: Not yet assigned

Art Unit: Not yet assigned

COMMUNICATION UNDER

37 C.F.R. § 1.821(e)

AND

PRELIMINARY AMENDMENT

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825 mailed October 13, 2005, Applicants submit that the computer-readable form in the instant application is identical with the Sequence Listing filed in Application No. 09/816,028, submitted September 10, 2001. In accordance with 37 C.F.R. § 1.821(e), please use the last-filed computer-readable form filed in Application No. 09/816,028 as the computer-readable form for the instant application. A paper copy of the Sequence Listing from Application No. 09/816,028 is submitted herewith. The information in the paper copy of the Sequence Listing is identical to

Appl. No. 10/734,719
Amdt. dated December 13, 2005
Reply to Notice to Comply of October 13, 2005

PATENT

that which is in the computer readable form submitted on September 10, 2001, as required under 37 C.F.R. § 1.821(f).

It is understood that the Patent and Trademark Office will make the necessary changes in application number and filing date for the computer-readable form that will be used for the instant application.

Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

Amendments to the Specification begin on page 3 of this paper.

Remarks begin on page 6 of this paper.